<DOC>
	<DOCNO>NCT02851849</DOCNO>
	<brief_summary>The purpose study evaluate change baseline hemoglobin A1c ( HbA1c ) 12 week treatment 3 dose level LGD-6972 compare placebo subject Type 2 Diabetes Mellitus ( T2DM )</brief_summary>
	<brief_title>A Study LGD-6972 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This 12-week , randomize , double-blind , placebo-controlled , 4-arm , parallel group , multi-center study evaluate safety efficacy LGD-6972 subject T2DM inadequately control metformin monotherapy ( stable [ ≥12 week ] , daily dose ≥1000mg randomization ) . Subjects T2DM treat one 3 dose level LGD-6972 ( 5 mg , 10 mg , 15 mg ) placebo daily ( QD ) 12 week . Randomization stratify HbAlc ≤8.5 % &gt; 8.5 % Placebo Lead-in Visit . Qualified subject require adjustment stabilization metformin dose participate run-in period 12 additional week prior randomization . Subjects option participate oral glucose tolerance test ( OGTT ) baseline end treatment assessment exploratory endpoint .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Female subject must surgically sterile ( hysterectomy bilateral oophorectomy bilateral tubal ligation ) , naturally postmenopausal least 12 month follicle stimulate hormone ( FSH ) level postmenopausal range ( take hormone replacement therapy ) 2 . Male subject must either vasectomy agree female partner use 2 acceptable form contraception , one must condom , 30 day last dose study drug . Other acceptable form contraception include hormonal contraceptive stable dose 12 week prior randomization , intrauterine device , DepoProvera® , Norplant® System Implants , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , contraceptive sponge , foam , jelly . Also , male subject must donate sperm study 30 day last dose study drug 3 . Willing able provide write informed consent 4 . Diagnosis T2DM accord American Diabetes Association criteria 5 . Currently stable metformin metformin extendedrelease therapy ( unchanged dose [ minimum daily dose 1000 mg ] ≥12 week prior screen ) 6 . Subjects must HbA1c value ≥7.0 % ≤10.5 % 7 . Subjects must fast plasma glucose ≤260 mg/dL 8 . Subjects must body mass index ( BMI ) 25 kg/m2 40 kg/m2 , inclusive , must weigh 45 kg 1 . History type 1 diabetes mellitus history diabetic ketoacidosis persistent hypoglycemia hypoglycemia unawareness 2 . Women childbearing potential , lactating , positive pregnancy test 3 . History presence alcoholism drug abuse within 2 year prior screen 4 . Unwilling comply study restriction , include restriction strenuous exercise 5 . Presence follow condition : renal impairment ( defined history estimate glomerular filtration rate screen &lt; 45 mL/min use Modification Diet Renal Disease equation ) , diabetic proliferative retinopathy , severely symptomatic diabetic neuropathy require treatment , diabetic gastroparesis , active liver disease ( asymptomatic nonalcoholic fatty liver disease ) , cirrhosis , symptomatic gall bladder disease , pancreatitis 6 . Serum triglyceride level &gt; 400 mg/dL screen 7 . Liver transaminase level ( AST ALT ) &gt; 150 % ULN , total bilirubin &gt; 2 ULN , creatine kinase ( CK ) level &gt; 3 × ULN screen 8 . History evidence clinically significant cardiovascular , pulmonary , renal , endocrine ( T2DM ) , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal , metabolic disease surgical intervention ( eg , bariatric surgery ) allergic condition ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) 9 . Myocardial infarction , unstable angina , arterial revascularization , stroke , symptomatic peripheral artery disease , deep vein thrombosis , New York Heart Association Functional Class III IV heart failure , transient ischemic attack within 6 month prior screen 10 . History malignant hypertension recent history uncontrolled high blood pressure screen seat systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg least 5 minute rest . Blood pressure determine mean triplicate measurement collect 2 minute interval subject sit quietly least 5 minute . Therapy hypertension ( beta blocker exclude ) stable least 8 week prior screen permit 11 . Arm size excess maximum limit large cuff provide study blood pressure monitor 12 . History malignancy ( except adequately treat basal squamous cell skin cancer cervical carcinoma situ ) within 5 year prior screen 13 . History evidence QT prolongation clinically significant QT prolongation ( QTcF &gt; 450 msec ) screening , significant ECG finding screen may place subject increase risk participate study 14 . Treatment type insulin ( inject inhale ) &gt; 6 consecutive day within 6 month prior screen insulin therapy within 12 week prior screen 15 . Treated peroxisome proliferatoractivated receptorgamma agonist ( thiazolidinediones [ TZDs ] ) , incretin therapy ( GLP1 agonists ) . amylin mimetics within 12 week prior screen 16 . Taking follow prohibited medication Antidepressants , antipsychotic , antiepileptic , hormone replacement therapy ( estrogen , progestin ) , testosterone therapy , thyroid replacement medication stable dose least 12 week prior screen Lipidmodifying medication antihypertensive medication stable dose least 8 week prior Screening Visit ( exclude bile acid sequestrants , ezetimibe , beta blocker , prohibit Overthecounter herbal medication supplement ( aside daily multivitamin ) 17 . Treatment systemic corticosteroid , must discontinue least 4 week prior screen . Note : Inhaled , intraarticular , intranasal topical corticosteroid permit 18 . Currently treat weightloss medication . These must discontinue ≥12 week prior screen 19 . History evidence intravenous illicit drug use , active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , and/or human immunodeficiency virus ( HIV ) infection 20 . Known hypersensitivity idiosyncratic reaction glucagon receptor ( GCGR ) antagonists LGD6972 21 . Participation another interventional clinical trial within 30 day prior dose treatment investigational product 14 day 5 halflives Screening Visit ( whichever longer ) 22 . Donated ≥ 450 mL blood within 56 day screen donate blood product within 30 day screen 23 . Inability comply study procedure adhere studyrequired restriction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>